Um Estudo Multicêntrico sobre Regurgitação Atrioventricular na Cardiomiopatia Amiloide por Transtirretina: Definição, Prevalência e Impacto Prognóstico.

This study is looking for adults aged 18 or older who have already been diagnosed with a specific heart condition called transthyretin amyloid cardiomyopathy (ATTR-CM). To join, your doctors would need to have already checked your heart carefully using a scan called an echocardiogram, preferably around the time of your diagnosis, to look at your heart valves.

It's important that you are willing to take part in the study and are able to formally agree to do so. This means understanding what the study involves and signing a consent form.

You wouldn't be able to join if you have a severe problem with another heart valve called the aortic valve that needs an operation. Also, if for any reason you can't understand the study or follow its instructions, you wouldn't be able to participate.

This study is a ‘registry study’, which means it primarily involves collecting and looking at information that doctors already gather during a patient's routine care. You wouldn't be asked to take any new medications just for this study. The main part of participating would involve allowing the researchers to use information from your existing medical records, especially details from your heart scans (echocardiograms).

The study would involve reviewing your medical history, particularly information about your ATTR-CM diagnosis and any heart valve issues. Researchers would also collect information on your health and how you are doing over time. You wouldn't need extra visits or assessments beyond your usual medical appointments. The total duration of your participation would depend on how long the researchers choose to follow your health information after you join.